Press Releases
M-LIFE™ Multi-targeting Cancer Drug Prospect MLS-222QLD Successfully Advancing Through Pre-Clinical Testing
M-Life’s™ Molecular Systems Approach is Proving Itself as the Next Generation for Drug Discovery NASHVILLE, TENNESSEE – M-LIFE™ announced the successful advancement of its anti-cancer prospect MLS-222QLD in preclinical testing. This molecule is one of several...
iCFO Capital recently partnered with Moskal Lifesciences to raise $3.5M seed funding
SAN DIEGO, CALIFORNIA, DECEMBER, 2021 – iCFO Capital recently partnered with Moskal Lifesciences, LLC to raise $3.5M seed funding for expand growth from iCFO Capital investor network in San Diego, California. Moskal Lifesciences, LLC uses Novel Algorithms to Identify...
M-Life™ Novel IL-6 Molecules and Efficacy/Toxicity Data
M-Life’s™ Molecular Systems Approach Enables Understanding of Efficacy and Toxicity Origins at the Atomic Level Leading to the Next Generation for Drug Discovery NASHVILLE, TENNESSEE – M-LIFE™ announced the successful conclusion of IL-6 molecular systems milestone...
M-Life™ COVID-19 Cytokine Storm Repurposing Possibilities
NASHVILLE, TENNESSEE – M-LIFE™ has identified 8 drugs as prospective repurposing targets to address the cytokine storm associated with severe COVID-19 cases. As with M-Life’s™ prior list of repurposing targets directed at the virus, prospective cytokine candidates...